289 related articles for article (PubMed ID: 11902567)
21. [Home palliative care--2 case reports: a long-term cancer pain management with transdermal fentanyl].
Fujimoto M; Sakuyama T; Mizutani Y; Kuroda T; Yanaga K
Gan To Kagaku Ryoho; 2004 Dec; 31 Suppl 2():190-3. PubMed ID: 15645768
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain.
Miyazaki T; Hanaoka K; Namiki A; Ogawa S; Kitajima T; Hosokawa T; Ishida T; Nogami S; Mashimo S
Clin Drug Investig; 2008; 28(5):313-25. PubMed ID: 18407717
[TBL] [Abstract][Full Text] [Related]
23. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers.
Mystakidou K; Parpa E; Tsilika E; Katsouda E; Kouloulias V; Kouvaris J; Georgaki S; Vlahos L
J Pain; 2004 Mar; 5(2):119-32. PubMed ID: 15042520
[TBL] [Abstract][Full Text] [Related]
24. Three-cycle fentanyl patch system significantly improves pain control in gynecologic cancer.
Kanamori C; Kanamori T; Hayashi M; Yorioka H; Kanzaki H
J Obstet Gynaecol Res; 2006 Dec; 32(6):605-9. PubMed ID: 17100824
[TBL] [Abstract][Full Text] [Related]
25. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Mitra F; Chowdhury S; Shelley M; Williams G
Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
[TBL] [Abstract][Full Text] [Related]
26. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.
Jeal W; Benfield P
Drugs; 1997 Jan; 53(1):109-38. PubMed ID: 9010652
[TBL] [Abstract][Full Text] [Related]
27. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
Allan L; Hays H; Jensen NH; de Waroux BL; Bolt M; Donald R; Kalso E
BMJ; 2001 May; 322(7295):1154-8. PubMed ID: 11348910
[TBL] [Abstract][Full Text] [Related]
28. [The opioid combination of transdermal fentanyl and sustained release morphine for refractory cancer pain--a case report].
Shinjo T; Okada M
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1997-2000. PubMed ID: 16282744
[TBL] [Abstract][Full Text] [Related]
29. The effectiveness of transdermal fentanyl in palliative care.
Evans R
Nurs Times; 2003 Oct 14-20; 99(41):24-5. PubMed ID: 14603653
[TBL] [Abstract][Full Text] [Related]
30. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.
Kornick CA; Santiago-Palma J; Moryl N; Payne R; Obbens EA
Drug Saf; 2003; 26(13):951-73. PubMed ID: 14583070
[TBL] [Abstract][Full Text] [Related]
31. Use of intravenous fentanyl against morphine tolerance in breakthrough cancer pain: a case series and literature review.
Hwang IC; Bruera E; Park SM
Am J Hosp Palliat Care; 2014 Feb; 31(1):109-11. PubMed ID: 23345613
[TBL] [Abstract][Full Text] [Related]
32. The role of transdermal fentanyl patches in the effective management of cancer pain.
Gibbs M
Int J Palliat Nurs; 2009 Jul; 15(7):354-9. PubMed ID: 19648851
[TBL] [Abstract][Full Text] [Related]
33. [Validity of recommended minimum dose of prior morphine to initiate transdermal fentanyl patch in prescribing information - multicenter survey of on prescriptions by palliative care specialists in Japan].
Hashizume T; Tomiyasu S; Yomiya K; Yoshimoto T; Harada A; Matoba M;
Gan To Kagaku Ryoho; 2007 Jun; 34(6):897-902. PubMed ID: 17570968
[TBL] [Abstract][Full Text] [Related]
34. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine.
Payne R; Mathias SD; Pasta DJ; Wanke LA; Williams R; Mahmoud R
J Clin Oncol; 1998 Apr; 16(4):1588-93. PubMed ID: 9552070
[TBL] [Abstract][Full Text] [Related]
35. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.
Greiner W; Lehmann K; Earnshaw S; Bug C; Sabatowski R
Eur J Health Econ; 2006 Dec; 7(4):290-6. PubMed ID: 16983521
[TBL] [Abstract][Full Text] [Related]
36. Transdermal therapeutic fentanyl-system (TTS-F).
Mystakidou K; Katsouda E; Tsilika E; Parpa E; Vlahos L
In Vivo; 2004; 18(5):633-42. PubMed ID: 15523905
[TBL] [Abstract][Full Text] [Related]
37. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain.
Wong JO; Chiu GL; Tsao CJ; Chang CL
Acta Anaesthesiol Sin; 1997 Mar; 35(1):25-32. PubMed ID: 9212478
[TBL] [Abstract][Full Text] [Related]
38. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
39. Transdermal fentanyl in cachectic cancer patients.
Heiskanen T; Mätzke S; Haakana S; Gergov M; Vuori E; Kalso E
Pain; 2009 Jul; 144(1-2):218-22. PubMed ID: 19442446
[TBL] [Abstract][Full Text] [Related]
40. Fentanyl transdermal system. Pain management at home.
Woodroffe MA; Hays H
Can Fam Physician; 1997 Feb; 43():268-72. PubMed ID: 9040914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
